Joseph Samuel Bertino
About
Joseph S. Bertino, PharmD, is a clinical pharmacologist and pharmacotherapy specialist based in Schenectady, New York. His work centers on clinical pharmacokinetics, drug metabolism, and the application of pharmacological principles to patient care and research, with particular attention to cytochrome P450 enzyme activity, drug exposure estimation, and population pharmacokinetic modeling.
With more than 760 peer-reviewed publications, Bertino has contributed across a broad range of pharmacological and oncological topics. His work appears in journals including the Journal of Clinical Pharmacology, Pharmacology and Therapeutics, Nature Cancer, Oncotarget, and the European Journal of Clinical Pharmacology. Recent publications reflect collaborations on cancer biology, including studies on breast cancer metastasis and tumor metabolism, as well as foundational work in clinical pharmacokinetics education. He has also published on bioethical questions in clinical care, including consent standards for brain-death testing and the role of clinical ethicists in inpatient settings.
Bertino holds licensure in New York and carries a specialty designation in pharmacotherapy. The breadth of his publication record, spanning basic science, translational oncology, and clinical pharmacology methodology, positions him to offer expert analysis in matters involving drug dosing, pharmacokinetic modeling, drug interactions, and related pharmaceutical standards of practice.
Publications
- Clinical Pharmacokinetics From the Beginning: A Practical Approach.
- Small-molecule inhibitors that disrupt the MTDH-SND1 complex suppress breast cancer progression and metastasis.
- Correction: Discovery and clinical introduction of first-in-class imipridone ONC201.
- In cancer, all roads lead to NADPH.
- S-warfarin limited sampling strategy with a population pharmacokinetic approach to estimate exposure and cytochrome P450 (CYP) 2C9 activity in healthy adults.
- Anti-Tumor Effects of a Penetratin Peptide Targeting Transcription of E2F-1, 2 and 3a Is Enhanced When Used in Combination with Pemetrexed or Cisplatin.
- Requiring Consent for Brain-Death Testing: A Perilous Proposal.
- The necessity of clinical ethicists for inpatient care.
- NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview.
- Rapid Assessment of Surface Markers on Cancer Cells Using Immuno-Magnetic Separation and Multi-frequency Impedance Cytometry for Targeted Therapy.
Request CV and rates
Tell us about your case and we'll connect you with Joseph Samuel Bertino within two business days.
Other experts
Verified specialists available for your case.
